Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/6604480.pdf
Reference30 articles.
1. Ardizzoni A, Tjan-Heijnen VC, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H, Dziadziuszko R, Burghouts J, Van Meerbeeck JP, Gans S, Legrand C, Debruyne C, Giaccone G, Manegold C (2002) Standard vs intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. J Clin Oncol 20: 3947–3955
2. Auperin A, Arriagada R, Pignon JP, Le Pechoux C, Gregor A, Stephens RJ, Kristjansen PE, Johnson BE, Ueoka H, Wagner H, Aisner J (1999) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341: 476–484
3. Buccheri G, Ferrigno D (2004) Prognostic factors of small cell lung cancer. Hematol Oncol Clin North Am 18: 445–460
4. Bunn Jr PA, Greco FA, Einhorn L (1986) Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer. Semin Oncol 13: 45–53
5. Cerny T, Blair V, Anderson H, Bramwell V, Thatcher N (1987) Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer 39: 146–149
Cited by 42 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer;Current Oncology;2023-06-30
2. Head and neck small-cell carcinoma: A multicenter study of 39 cases from 10 institutions;Frontiers in Surgery;2022-11-14
3. Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients;Translational Lung Cancer Research;2022-09
4. FRESC: French Real world Extensive stage SCLC Cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-2010;Lung Cancer;2022-02
5. HER2 targeting near‐infrared photoimmunotherapy for a CDDP‐resistant small‐cell lung cancer;Cancer Medicine;2021-11-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3